Cargando…
肺癌抗血管生成治疗：现状、进展与困惑
Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Adva...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051307/ https://www.ncbi.nlm.nih.gov/pubmed/35477192 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.16 |
| _version_ | 1784696524411764736 |
|---|---|
| collection | PubMed |
| description | Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Advanced lung cancer patients, no matter different groups or different stages of the disease, are benefited from anti-angiogenes. In this paper, based on the clinical status and unsolved problems, combined with the latest clinical and translational research data, we reviewed the current anti-angiogenesis treatment of lung cancer. |
| format | Online Article Text |
| id | pubmed-9051307 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90513072022-05-11 肺癌抗血管生成治疗：现状、进展与困惑 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Advanced lung cancer patients, no matter different groups or different stages of the disease, are benefited from anti-angiogenes. In this paper, based on the clinical status and unsolved problems, combined with the latest clinical and translational research data, we reviewed the current anti-angiogenesis treatment of lung cancer. 中国肺癌杂志编辑部 2022-04-20 /pmc/articles/PMC9051307/ /pubmed/35477192 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.16 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
| spellingShingle | 综述 肺癌抗血管生成治疗：现状、进展与困惑 |
| title | 肺癌抗血管生成治疗：现状、进展与困惑 |
| title_full | 肺癌抗血管生成治疗：现状、进展与困惑 |
| title_fullStr | 肺癌抗血管生成治疗：现状、进展与困惑 |
| title_full_unstemmed | 肺癌抗血管生成治疗：现状、进展与困惑 |
| title_short | 肺癌抗血管生成治疗：现状、进展与困惑 |
| title_sort | 肺癌抗血管生成治疗：现状、进展与困惑 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051307/ https://www.ncbi.nlm.nih.gov/pubmed/35477192 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.16 |
| work_keys_str_mv | AT fèiáikàngxuèguǎnshēngchéngzhìliáoxiànzhuàngjìnzhǎnyǔkùnhuò AT fèiáikàngxuèguǎnshēngchéngzhìliáoxiànzhuàngjìnzhǎnyǔkùnhuò |